A Case of High Dose Oseltamivir Treatment in an Influenza A (H1N1) Infected Patient with Severe Graft Versus Host Disease
- Author:
Ah Reum KIM
1
;
Eun Sim KIM
;
Ki Soo PAI
;
Jun Eun PARK
Author Information
1. Department of Pediatrics, Ajou University School of Medicine, Suwon, Korea. pedpje@ajou.ac.kr
- Publication Type:Case Report
- Keywords:
H1N1 virus;
Graft vs host disease;
Transplantation;
Homologous
- MeSH:
Graft vs Host Disease;
Hematopoietic Stem Cell Transplantation;
Humans;
Immunocompromised Host;
Influenza A Virus, H1N1 Subtype;
Influenza, Human;
Lung;
Neuroblastoma;
Oseltamivir;
Real-Time Polymerase Chain Reaction;
Siblings;
Skin;
Tissue Donors;
Transplants
- From:Clinical Pediatric Hematology-Oncology
2011;18(1):58-61
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Influenza A (H1N1) infection has been noted to be common in the young and high-risk groups for influenza infection, including transplant candidates and recipients. However, the optimal dosage and duration of oseltamivir for severely immunocompromised patients have not been defined. We report the case of a patient with relapsed neuroblastoma who was infected with influenza A (H1N1) and suffered from skin and lung graft versus host disease after he had received allogeneic hematopoietic stem cell transplantation from a matched sibling donor. During the immunosuppressant therapy, he was diagnosed with influenza A (H1N1) infection by real time polymerase chain reaction (RT-PCR). He recovered after oseltamivir treatment with a dosage of 90 mg twice a day for two weeks, which was two times of the standard dose until influenza A (H1N1) RT-PCR was proven to be negative.
